News

Vytrus Biotech is one of the 10 companies selected for the BIOMED ScaleUp business acceleration program by CataloniaBio & HealthTech.

Beauty Cluster organizes the sixth edition of the Beauty Innovation Days (6th BIDs), the annual event of the cosmetic industry benchmark, where a 360º view of the latest innovations of the entire value chain of the industry will be presented.

Happy Christmas from Vytrus! After this difficult year plenty of changes, social distancing and loneliness, the WISH of the whole VYTRUS team for these special dates is that we do not [...]

The Vytrus’s cofounder and Scientific Director is interviewed by Cosmetics Business about its 2020 prize-winning ingredients and the plant stem cell technology behind them.

EcoVadis recognized the Silver Medal to Vytrus for its good practices in terms of sustainability, actions, processes and systems of Corporate Social Responsibility.

Funding from the Ministry of Science and Innovation aims to execute a 3-year “Retos Collaboration” project in which new revolutionary skin treatments will be developed.

Vytrus Biotech has been double-awarded to the most innovative ingredients in the world in the category ‘Best Ingredient Award 2020’ at In-cosmetics global.

The first online edition of Beauty Sustainability Week will be held from September 28th to October 2nd and Vytrus Biotech will take part at the event, where novelties and new solutions implemented in sustainability and CSR in the cosmetic industry will be shown.

The biotechnology company has been selected as a finalist for its two new cosmetic ingredients in the category ‘Best Ingredient Award 2020’ at In-cosmetics global.

Vytrus Biotech and IRTA announce their agreement to research and preserve 80 traditional varieties of olive tree in Catalonia.

Vytrus Biotech has recently adapted its processes to collaborate altruistically in the sterilization of masks for Sant Quirze del Vallès City Council, a town in Barcelona.

Vytrus Biotech informs its customers, distributors, suppliers and collaborators that in the current situation of COVID-19 we will continue with normal activity and operations in order to fulfil its commercial obligations and commitments acquired